Olmesartan increases toxicity of lithium by decreasing renal clearance. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. Ivosidenib will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Idelalisib is a strong CYP3A inhibitor avoid coadministration with sensitive CYP3A substrates Idelalisib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration may increase risk for adverse effects of CYP3A4 substrates. Avoid or Use Alternate Drug.įexinidazole will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor increased effects and toxicities (eg, bradycardia, sinus arrest, decreased cardiac output) if amiodarone is concomitantly used with nondihydropyridine calcium channel blocker (ie, diltiazem).Įnzalutamide will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use with amlodipine and diltiazem reported an a 60% increase in amlodipine AUC. Give a low dose of calcium channel blockers initially and increase only ECG is reviewed and tolerated.ĭiltiazem will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Calcium channel blockers with depressant effects on the sinus and AV nodes could potentiate dronedarone's effects on conduction. Avoid or Use Alternate Drug.Ĭonivaptan will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.Ĭhloroquine will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.Ĭhloramphenicol will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose according to prescribing information if needed.Įither increases toxicity of the other by pharmacodynamic synergism.
Evaluate for loss of therapeutic effect if medication must be coadministered. Avoid or substitute another drug for these medications when possible. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. If not feasible, avoid use of abametapir.Īpalutamide will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. Rare incidence of cardiovascular collapse and marked hyperkalemia observed when coadministered may be higher risk with nondihydropyridine calcium channel blockers.Ībametapir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor renal function periodically.Įither increases toxicity of the other by Mechanism: pharmacodynamic synergism.
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of ARBS with drugs that affect RAAS may increase the risk of renal impairment (including acute renal failure) and cause loss of antihypertensive effect. Contraindicated.Ĭomment: Aliskiren use contraindicated with ARBs in patients with diabetes avoid coadministration with ARBs if GFR. You may report side effects to FDA at 1-80.Olmesartan decreases effects of aliskiren by Other (see comment). Call your doctor for medical advice about side effects. This is not a complete list of side effects and others may occur. high potassium level-nausea, weakness, tingly feeling, chest pain, irregular heartbeats, loss of movement.a light-headed feeling, like you might pass out or.pounding heartbeats or fluttering in your chest.
0 kommentar(er)
